Insilico and Qilu Forge $120M AI Alliance to Target Cardiometabolic Disease
Insilico Medicine and Qilu Pharmaceutical launch an AI-driven collaboration worth up to $120M to discover small molecules for cardiometabolic diseases.
Insilico and Qilu Forge $120M AI Alliance to Target Cardiometabolic Disease Read More »










